5/23/2022 7:32:34 AM
Soligenix Receives US Patent Allowance For Thermostabilized Vaccine Platform
5/13/2022 7:39:30 AM
Soligenix March Quarter Revenues $0.2 Mln Vs. $0.1 Mln Prior Year
4/19/2022 7:38:08 AM
Soligenix Gets $1.4 Mln In Non-Dilutive Government Funding
3/29/2022 7:32:59 AM
Soligenix FY Net Loss $12.6 Mln Or $0.31/shr Vs. Loss $17.7 Mln Or $0.64/shr Prior Year
3/17/2022 7:33:34 AM
Soligenix Says COVID-19 Vaccine, CiVax, Boosts Neutralizing Activity Against SARS-CoV-2, Incl Delta And Omicron
1/4/2022 7:37:40 AM
Soligenix : Dusquetide Shows Positive Anti-tumor Efficacy In Multiple Nonclinical Animal Studies; Stock Up
11/12/2021 7:35:28 AM
Soligenix Q3 Revenues $0.2 Mln Vs. $0.6 Mln Prior Year
11/8/2021 7:33:03 AM
Soligenix Granted Pediatric Investigational Plan Waiver For HyBryte In CTCL In United Kingdom
9/28/2021 7:39:49 AM
Soligenix Announces Efficacy And Broad Neutralizing Activity Of Its COVID-19 Vaccine CiVax In Non-Human Primates
9/9/2021 7:34:24 AM
Soligenix: FDA Grants Orphan Drug Designation For Treatment Of T-cell Lymphoma
8/23/2021 7:36:36 AM
Soligenix Reports Publication Showing Formulation, Heat Stabilization Of Filovirus Vaccine Platform For Ebola
8/13/2021 7:35:33 AM
Soligenix Q2 Revenues Decline To $0.2 Mln From $0.5 Mln Prior Year
6/22/2021 7:45:21 AM
HyBryte Says Positive Pivotal Phase 3 FLASH Study Selected For Presentation At USCLC Annual Meeting
6/10/2021 7:32:39 AM
Soligenix Gets Pediatric Investigational Plan Waiver From EMA For HyBryte In Cutaneous T-cell Lymphoma